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A key aspect of the authority for regulating genetically engineered crops is the legal basis 
of that authority. For example, in contrast to what some people think, the Food and Drug 
Administration (FDA) cannot make consultation mandatory, because there is no law to 
permit it. In 99, FDA published an article in the Federal Register—The Statement of 
Policy: Foods Derived from New Plant Varieties—in which was discussed its legal framework 
for considering new plant varieties as a whole, including genetically engineered varieties. 
The article’s focus was chiefly on elements already in the Food, Drug, and Cosmetic Act 
(FD&C Act), and it explained the agency’s thinking about safety and regulatory issues 
pertaining to new plant varieties, based on several parts of existing food law.
The first issue is adulteration, the second is food additives, and the third is labeling 
(Figure ). There are two basic elements to US food law. The first is the responsibility 
of purveyors—which include crop developers, farmers, and manufacturers—to ensure 
that the foods they market are safe, wholesome, and comply with all applicable legal and 
regulatory requirements. The second element is what FDA does to enforce the law, using 
regulatory tools to remove unsafe or illegal foods and ingredients from the marketplace. 
These include seizures, recalls, and denial of entry of food from abroad.
We have a program to help developers ensure that food from new plant varieties is safe 
and complies with laws and regulations. Three legal requirements are applicable.
• Safety: The food is as safe as that generated from traditionally bred varieties.
• Labeling: The food labeling is truthful and not misleading.” 
• Additives: Is premarket review required?
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Figure . FDA’s authority: the FD&C Act.
Figure . FDA’s legal framework for foods from new plant varieties.
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FDA’s Authority
There are two basic elements to FDA’s authority. The first is post- market authority (Figure 
), under the adulteration provision of the FD&C Act, which, generally, applies to whole 
foods. A food is considered adulterated if it contains a poisonous or otherwise deleteri-
ous substance known to harm humans or animals, if it contains an unsafe food additive, 
or if it contains an unsafe pesticidal chemical. The second element is FDA’s premarket 
authority governing food additives, unless data show that they are generally recognized 
as safe (“GRAS”) by qualified experts in their intended use.
Under what circumstances would a food additive be present in a genetically engineered 
plant? It would be a new protein or the product of a new protein for which safety informa-
tion is not publicly available or widely accepted. Accordingly, FDA would require a review 
before marketing. So far, the only example of a food additive in a genetically engineered 
plant was the NPTII enzyme used as a selective marker in the FlavrSavr tomato. At the 
time Calgene submitted its food-additive petition, there was no experience with using 
proteins of this type in food.
Labeling
According to the “misbranding” part of the FD&C Act, a label on a food must be truthful 
and not misleading. A label must be changed if a meaningful difference is created by confer-
ring a change in a food; it must be called something different. To date, the best examples 
are modified oil crops, e.g. high oleic acid soybean and stearidonic acid soybean. 
1992 Policy
In summary, the 99 policy considers whether the product in question is as safe as other 
foods. It provided guidance to industry via decision trees and includes a suggestion that 
developers consult with FDA early in the development process, so that potential issues 
may be identified before they become problems.
CFSAN and CVM
Submissions to FDA are evaluated by two centers for different uses. Safety of use in hu-
man food is evaluated by the Center for Food Safety and Applied Nutrition (CFSAN), 
whereas the Center for Veterinary Medicine (CVM) evaluates safety of use in animal 
feed. Again, we advise early consultations at FDA to advise us of what you are doing, 
then return to the lab to run tests for potential toxicity, allergenicity and antinutrient 
content, and potential for bioavailability alteration. This is followed by submission of 
a dossier—hopefully not too lengthy—describing why the use of the plant as food or 
would be safe and legal.
What are the issues? Regarding safety, there’s the potential for toxicity, the potential for 
allergenicity, and for changes in levels of anti-nutrients and in bioavailability. Regarding 
regulatory considerations, there’s the question of whether a new substance is an unap-
proved food additive or GRAS, or whether there’s a meaningful change requiring a new 
common or usual name.
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In essence, we ask people to tell us their story—about their new plant variety and why 
it’s safe for food use. As for FDA’s role, we recognize that there’s widespread variation 
in plants in nature, including among domesticated varieties, affected by environmental 
conditions and the genetic background (Figure 3). We have developed a process whereby 
we evaluate final submissions and if there are aspects we don’t understand, we will seek 
clarification. We then develop our own document, and conclude by sending a letter. We 
mail the letter to the submitter and place a memo on our website—a scientific evaluation 
that establishes whether the new variety is as safe as those already in the marketplace.
We added a new piece in 006. When preparing for field trials with a protein that hasn’t 
been used before, our early food-safety evaluation (Figure 4) is worthy of consideration. 
This guidance is termed a “new protein consultation” (NPC). If a new protein is neither 
toxic nor allergenic, then it would be considered safe for field testing and FDA would 
not be concerned if low levels appeared inadvertently in the marketplace. 
Figure 3. Consultation procedures: FDA’s role.
Safety Assessment
As far as safety assessment is concerned, we understand that agronomic and quality issues 
will eliminate some lines from consideration at the very beginning of the process (Figure 5). 
We need to have information on new substances, including identity and source, using the 
weight-of-evidence approach. And we need to look at composition, and perhaps at some 
agronomic aspects. The intended effects must be clarified in terms of overall effects on 
the food and compositional changes. And, finally, unintended effects may be important. 
Does the insertion result in expression of (a) new or altered protein(s), or even fusion 
proteins? Are there unanticipated actions of a new enzyme on other components within 
the plant?
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Figure 4. Early food-safety evaluations (NPCs).
Figure 5. Safety assessment–.
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Figure 6. Safety assessment–.
The safety of genetically engineered plants for food and feed is judged using a case-
by-case approach. Generally, the genetically engineered plant is compared with a closely 
related conventionally developed plant, with the focus on new substances, i.e. toxicants, 
anti-nutrients, allergens and toxins. Bioinformatics are used to address the possibility 
that unintended new proteins are likely to be expressed, and if so, are they safe? The 
sequences of new proteins are compared with the sequences of known toxins, allergens 
and anti-nutrients.
For the molecular assessment, we require several pieces of information (Figure 7):
• Data showing which portions of the introduced DNA have been incorporated 
into the plant’s genome.
• Confirmation that there’s no vector backbone, with examination of the fidelity of 
insertion of the construct.
For safety assessments, three basic components are applicable (Figure 6). Genetic 
analysis focuses on stability and unintended effects. Chemical and nutritional analyses 
focus on dietary impacts and toxicant levels. And allergenicity and, to a lesser degree, 
toxicity are assessed. Resources for use in safety assessments can be pooled from the 
 following sources:
• The Statement of Policy on FDA’s website.
• The Codex Alimentarius guidelines.
• Guidelines set out by the Organization for Economic Cooperation  and Develop-
ment (OECD).
We have certain flexibility about format and how the necessary information is presented 
to us. 
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Figure 7. The molecular assessment.
Figure 8. Compositional analyses.
• Evidence that no unintended proteins resulted from open reading frames. 
 Ordinarily, that’s based on bioinformatic analysis of the junction sequences of 
the insert.
• Information about copy number and stability, using genomic DNA blots or other 
appropriate technologies. 
Next, compositional analyses are generally performed on field tests at multiple sites 
and usually over two growing seasons. The objective is to ensure that nutritional value 
is conserved, by comparing the new genetically engineered variety with a related control 
and/or a similar entity in the marketplace. Figure 8 illustrates the process for row crops. 
Key nutrients comprise proximates, i.e. fatty acids, fibers, amino acids, and vitamins 
and minerals. Again, we look at anti-nutrients, endogenous toxicants and endogenous 
allergens. For other types of crops, the analyses may be less comprehensive; in the case of 
fruit, the analyses usually comprise mostly fiber and sugar.
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Figure 0. Types of traits.
Figure 9. Traits and crops evaluated by FDA.
Experience to Date
Corn, cotton, soybean, and canola have been the focus of most of our consultations. 
We have seen many varieties of these crops. Traits that we’ve covered can be classified as: 
herbicide tolerance, virus and insect resistance, altered oil composition, male sterility, 
delayed ripening, other altered composition, and agronomic changes (Figure 9).
As for the types of traits, we can group them in three basic categories (Figure 0). 
Both EPA and FDA have roles to play in assessing plant-incorporated protectants (PIPs). 
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Figure . Transparency.
Generally, FDA looks at stability and nutritional composition, whereas EPA looks at 
 human and environmental safety via genomics and proteomics. For non-pesticidal pro-
teins, FDA alone looks at food and feed safety. And FDA has had some submissions that 
utilize RNA inhibition.
Risk Communication
Regarding risk communication, we try to be transparent to the degree that the law 
 allows. Our inventory is available on the Internet (right side of Figure ). If something 
is required of FDA that is not available on the Internet, a Freedom of Information Act 
request may be submitted. Also, we are happy to communicate directly via email, con-
ventional mail, or by telephone. Figure  provides a list of resources; our main page is 
www.fda.gov/geplantfoods.
Figure . FDA’s Internet resources.
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In Conclusion
Our safety evaluations are based on the premise that genetically engineered plants are as 
safe as their traditionally bred counterparts. We encourage developers to engage with us 
prior to marketing, and we communicate with our sister government agencies and inter-
national groups to ensure that we’re using both the best science and the best practices. We 
understand that, as science evolves, we will see new technologies and new traits; however, 
we expect that the policy that was developed in 99 will remain sufficiently flexible and 
broad to accommodate them.
